Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
株式のランク #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
株価
$1.51
最終同期: 2024-08-26
時価総額
$1.12M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Agile Therapeutics, Inc. (AGRX)

カテゴリー

Agile Therapeutics, Inc.(AGRX)の営業利益率
August 2026 時点の営業利益率 TTM: -101.49%
Agile Therapeutics, Inc. の最新の財務報告と株価によると、現在の営業利益率(TTM)は -101.49% です。2022 年末時点では -380.69% でした。
Agile Therapeutics, Inc. の営業利益率の履歴(2012 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -101.49% 0.00%
2023 -101.49% -73.34%
2022 -380.69% -78.01%
2021 -1,731.41% -73.56%
2020 -6,549.13% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
同業他社の営業利益率
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。